November 1, 2017 (Vol. 37, No. 19)

The Binding Site

Eight new recombinant antigens are available for in vitro diagnostic (IVD), manufacturing, and research applications. The recombinant Parvovirus NS1, VP1, VP2, VP2-VLP, PepA (VP1 unique), PepB (VP2 C-term), PepC (VP1 N-term), and PepD (VP1 C-term) have all been expressly designed for use as integral components within solid-phase enzyme immunoassay (EIA) test procedures, including ELISA. All of these antigens are sourced from an Escherichia coli-derived recombinant protein and exhibit exceptional purity levels as a result of unique chromatography techniques. They all feature an outstanding shelf-life stability claim of 10 years from the date of manufacture and are offered in a standard-sized 1.0-mg filled vial, with larger, bulk configurations also available.

Previous articlePumpkin Genomes Sequenced in Time for Halloween, Revealing Curious Evolution
Next articleAstraZeneca Asthma Candidate Tralokinumab Fails Two Phase III Trials